Discontinuation: Involuntary Discharge

Similar documents
Pain, Addiction & Methadone

Southlake Psychiatry. Suboxone Contract

Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop

EPIDEMIOLOGY OF OPIATE USE

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Medical Malpractice Treatment Alprazolam benzodiazepine - A Case Study

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier?

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

Urine Drug Testing Methadone 101 Methadone for hospitalists

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Question one. 1. You increase her to 90mg 2. You increase her to 95mg 3. You hold her dose where it is (80mg)

Triage, Assessment & Treatment

Treatment Approaches for Drug Addiction

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania

opiates alcohol 27 opiates and alcohol 30 April 2016 drug addiction signs 42 Ranked #1 123 Drug Rehab Centers in New Jersey 100 Top

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

Opioid overdose can occur when a patient misunderstands the directions

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Treatment Approaches for Drug Addiction

Opioid Addiction & Corrections

Financial Disclosures

Community Based Treatment and Care for Drug Use and Dependence

Treatment of opioid use disorders

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

POLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL

Medication-Assisted Addiction Treatment

Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis

Patients are still addicted Buprenorphine is simply a substitute for heroin or

DSM V criteria. Defining Opioid Use Disorder (Addiction)

Treatment System 101

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

DrugFacts: Treatment Approaches for Drug Addiction

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

OVERVIEW WHAT IS POLyDRUG USE? Different examples of polydrug use

Information for Pharmacists

Arkansas Emergency Department Opioid Prescribing Guidelines

Update and Review of Medication Assisted Treatments

Frequently asked questions

How To Treat Anorexic Addiction With Medication Assisted Treatment

THE DRUG DETOX UNIT AT MOUNTJOY PRISON A REVIEW

Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.

Patient Information and Consent to Treatment with Buprenorphine

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES

Treatments for drug misuse

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

Allyse Adams PC, LICDC Oriana House, Inc.

Treatment Approaches for Drug Addiction

Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence

Grant House APPLICATION

New Haven/Fairfield Counties Ryan White Part A Program Substance Abuse Service Standard SUBSTANCE ABUSE

Treatment Resources for Substance Use Disorders

Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

Magee-Womens Hospital

A Review of the Impacts of Opiate Use in Ontario: Summary Report

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

MEDICAL ASSISTANCE BULLETIN

Prescriber Behavior, Pain Treatment and Addiction Treatment

Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain

POLICY FOR A DRUG AND ALCOHOL-FREE WORKPLACE

Substance Use: Addressing Addiction and Emerging Issues

We re glad you are here! Agenda for the Day Breaks Lunch Q&A and note cards Phones

Tauto-Mod. Homeopathy for Addictions

Opiate Treatment for Aboriginal High School Students in Ontario

Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013

Karol Kaltenbach, PhD Maternal Addiction Treatment Education and. Jefferson Medical College Thomas Jefferson University

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009

Performance Standards

Using Drugs to Treat Drug Addiction How it works and why it makes sense

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

These changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level.

Methadone and Pregnancy

Intake Consultation and Assessment Before Detox. What Happens During Drug Detox?

Office-based Treatment of Opioid Dependence with Buprenorphine

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

How To Use Naltrexone Safely And Effectively

Criminal Justice Integrated Drug Teams and treatment interventions. Clinical guidance to maximise access to drug treatment

Drug and Alcohol Assessment

Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances

Opioid Treatment Services, Office-Based Opioid Treatment

MANAGEMENT OF CHRONIC NON MALIGNANT PAIN

2015 OPIOID TREATMENT PROGRAM DESCRIPTIONS

TREATMENT MODALITIES. May, 2013

Transcription:

Discontinuation: Involuntary Discharge TYPICALLY A PROCESS NOT AN EVENT

Objectives 2 Review indications for discharge. Develop a therapeutic approach, in the context of the nature of Substance Use Disorders. Explore the balance between patient-centred care and the need for staff safety and mutual respect.

Engagement Ensure the program expectations for urine drug screens, appointments, communication and mutual respect are well established at intake. Model the high level of professionalism required to work effectively with patients who may have concurrent mental health and addiction issues, marginalized lifestyles, poor life skills, criminality, a history of abuse, and low levels of trust. Work cooperatively, within your team, to maintain healthy boundaries with clients. 3

Pharmacy Related Discharge 4 Lack of pharmacy access, with no safe alternatives. Pharmacy discharge: typically shoplifting or abusive behaviour. Repeated pharmacy absences.

Abuse of staff. Program Related Discharges 5 Refusal to provide, or tampering with, UDS. Non-attendance.

Drug Use Discharge: Opioid Rare phenomenon. 6 Persistent opiate positive, typically fentanyl or heroin. Assertive dosing, reasonable expectation of a good blockade. Address triggers and pattern of use. Is methadone being used to mitigate withdrawal, and enable continued IVDU?

Drug Use Discharge: Stimulants More common. Cocaine, methylphenidate, methamphetamine. Cancel carries first, ask questions later. Recognize role of needle craving. Encourage detox, rehab, increased engagement in recovery work. If indicated, taper gradually: often the specter of daily opioid withdrawal stimulates reflection and change. 7

Stimulant Use Exception HIV positive, on ART linked to methadone. Even with continued stimulant use, people can achieve improved CD4 counts and undetectable viral loads. Continued engagement in care may lead to eventual stimulant extinguishment. In the interim this represents true Harm Reduction, with demonstrable efficacy, rather than addiction treatment. 8

The Discharge Process Can be immediate for egregious behaviour and nonparticipation. Typically a process however, emphasizing the need for active engagement. Provide enhanced support, as indicated. Taper dose gradually (5 mg. Q 2-4 weeks). Accelerate as indicated (5 mg. weekly). Leave the door open for their return. Emphasize the importance of their recovery work: this is not about the rules, their gaming, or power and control. 9

CPSS Guidelines: Involuntary Withdrawal 10 Consider when continuation of treatment presents an unreasonable risk to the patient, treatment staff, prescribers, pharmacy staff, or the public.

CPSS Standards: Involuntary Withdrawal 1) May transfer or discharge a patient if: Behaviour has been threatening, disruptive or violent. They have been consistently non-compliant with the treatment agreement. At high risk for an adverse outcome, and attempts to reduce the risk have failed. Diversion has been confirmed. 11

CPSS Standards: Involuntary Withdrawal 2) Daily witness during taper. 3) Ensure managing physician is an Initiating Physician. 4) Notify the CPSS of any discharges. 5) The physician must warn the patient about the loss of tolerance and the risk of toxicity (overdose) if they relapse. 12

CPSS Guidelines: Involuntary Withdrawal 13 1) Explain the reasons to the patient and document the rationale. 2) May use an aggressive schedule: 10% reduction per day, or 1 mg. per day, whichever is greater. 3) May use pharmacotherapy in the final 1 2 weeks to relieve withdrawal symptoms. 4) Encourage engagement with other health care professionals or a treatment program.

Involuntary Withdrawal: Case 1 A 29 year old male with long term poly-substance IVDU. HIV negative, HCV positive. Repeatedly avoids UDS. Reluctant to increase methadone dose but insistent on more morphine to address withdrawal. What would you do? 14

Involuntary Withdrawal: Case 1 B Same patient. Reluctantly provides UDS. Has completed opioid withdrawal and is on methadone alone. Dose adjustment continues. UDS remains positive for cocaine or crystal methamphetamine. Has begun to demand carries, at 6 weeks. What now? 15

Involuntary Withdrawal: Case 1 C 16 Same patient. UDS are opioid negative at 80 mg. OD. Still stimulant positive at 12 weeks. Misses appointments, frequently misses at the pharmacy and is challenging for the pharmacy staff to manage. (impatient, loud, demanding) He refuses to access detox and drug rehab services. What next?

Involuntary Withdrawal: Case 1 D 17 Repeated concerns over continued stimulant use and lack of engagement in accessing services persist at 6-8 months. A gradual taper is initiated, with sharing of the rationale. Commitment to stop the taper is given, with persistently stimulant negative UDS. As the taper progresses, at 5 mg. q 2 weeks, the patient appears to re-engage. UDS are now stimulant negative. What would you do?

Involuntary Withdrawal: Case 2 A 26 year old woman with 3 children has progressed well, with opioid negative UDS and successful progress in her vocational training program. She has earned 1:6 carries. CLH is released from jail. UDS now become cocaine positive. She does not return to school for the next semester. What now? 18

Involuntary Withdrawal: Case 2 B Carries are cancelled, but UDS remains cocaine positive. You step up your stimulant response plan: 1) offer increased counselling, detox and rehab, 2) explain your refusal to support her cocaine use and 3) share your next step of a tapered withdrawal. 19 Your interventions are ineffective.

Involuntary Withdrawal: Case 2 C The pharmacy complains of increasing conflict. Her children are highly disruptive, out of control, damaging displays and knocking stock from the shelves. She frequently yells, disrupts other customers, and argues with the staff. She is threatened with a pharmacy discharge, the only one in town to dispense methadone. What would you do? 20

Involuntary Withdrawal: Case 2 CD You negotiate a more rapid taper, but pharmacy services continue. Her UDS remain cocaine positive, opioid negative, until near the end. She relapses onto opioids, and requests continuation. What now? 21

Thank you! 22 QUESTIONS?